Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen

Prostate

Volumn 70, Issue 10, 2010, Pages 1127-1133

  Ide, Hisamitsu ^a   Tokiwa, Shino ^a   Sakamaki, Kentaro ^b   Nishio, Koujiro ^a   Isotani, Shuji ^a   Muto, Satoru ^a   Hama, Takanori ^c   Masuda, Hiroko ^d   Horie, Shigeo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Angfa Inc   (Japan)

^d SECOM SC Center   (Japan)

Author keywords

Curcumin; Isoflavones; Prostate cancer; PSA

Indexed keywords

ANDROGEN RECEPTOR; CURCUMIN; ISOFLAVONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; ISOFLAVONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER PREVENTION; CELL STRAIN LNCAP; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CURCUMIN; DOUBLE-BLIND METHOD; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 77953425009     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21147     Document Type: Article

References (32)

1. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: A cross-national study. J Natl Cancer Inst 1998;90(21):1637-1647. (Pubitemid 28523438)
2. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973;50(5):1137-1144.
3. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, Ahn YO, Shin MH, Lee CW, Lee DH, Blair A, Devesa SS, Hsing AW. Rising prostate cancer rates in South Korea. Prostate 2006;66(12):1285-1291.
4. Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, Goto K, Naito S, Fujimoto K, Hirao Y, Takahashi A, Tsukamoto T, Akaza H. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr 2007;137(8):1974-1979.
5. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev 2003;61(4):117-131.
6. Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate 2004; 59(2):141-147.
7. Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo. Clin Cancer Res 2004;10(15):5282-5292.
8. Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, Okugi H, Sekine Y, Oki K, Ito K, Yamamoto T, Fukabori Y, Kurokawa K, Yamanaka H. Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 2002;99(6):846-852.
9. Rice L, Samedi VG, Medrano TA, Sweeney CA, Baker HV, Stenstrom A, Furman J, Shiverick KT. Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts. Prostate 2002;52(3):201-212.
10. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S, Hursting SD. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000;29(2):92-102.
11. Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/ isoflavone diet. Prostate 2000;45(2):101-105.
12. Choi YH, Lee WH, Park KY, Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/ M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 2000;91(2):164-173.
13. Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G, Klocker H. Molecular effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer 2005;4(2):124-129. (Pubitemid 41474608)
14. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002;8(7):2369-2377. (Pubitemid 34753612)
15. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002;32(8):296-300.
16. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim WJ, Song JM, Pantuck AJ. Comparisons of percent equol producers between prostate cancer patients and controls: Case-controlled studies of iso-flavones in Japanese, Korean and American residents. Jpn J Clin Oncol 2004;34(2):86-89.
17. Von Löw EC, Perabo FG, Siener R, Muller SC. Review. Facts and fiction of phytotherapy for prostate cancer:Acritical assessment of preclinical and clinical data. In Vivo 2007;21(2):189-204. (Pubitemid 46534271)
18. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem Pharmacol 2007;75(4):787-809.
19. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20(52):7597-7609.
20. Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007; 67(5):1988-1996.
21. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 2000;89(1):123-134.
22. Salvioli S, Sikora E, Cooper EL, Franceschi C. Curcumin in cell death processes: A challenge for CAM of age-related pathologies. Evid Based Complement Alternat Med 2007;4(2):181-190.
23. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Prostate Cancer Prostatic Dis 2000;3(2):84-93. (Pubitemid 30665213)
24. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-224.
25. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294(1):66-70. (Pubitemid 41002840)
26. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 36,316 biopsies. Urology 2005;65(3):549-553.
27. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, Borkowski A, Schulman C, Marberger M. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J Urol 2001;166(3):856-860.
28. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21(1):3-16.
29. Bindukumar B, Schwartz SA, Nair MP, Aalinkeel R, Kawinski E, Chadha KC. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth. Neoplasia 2005; 7(3):241-252.
30. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int 2006;89(4): 1121-1134. (Pubitemid 44972063)
31. Maskarinec G, Morimoto Y, Hebshi S, Sharma S, Franke AA, Stanczyk FZ. Serum prostate-specific antigen but not testosterone levels decrease in a randomized soy intervention among men. Eur J Clin Nutr 2006;60(12):1423-1429.
32. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2003;47(2):111-117.